How does the cypionate ester differ from enanthate and propionate in terms of release profile?

Cypionate's eight-carbon ester tail produces an approximate 7–10 day active-release window per injection, sitting between propionate (2-carbon, 24–48 hour release, requiring every-other-day injections) and undecanoate (11-carbon, 2–4 week depot). Compared to enanthate (7-carbon), cypionate releases marginally more slowly due to its slightly longer chain, but the clinical difference is modest — both support weekly or twice-weekly injection schedules with comparable serum stability.

Which testosterone ester is best suited to a strength-focused bulking phase versus a recomposition goal?

For bulking phases where injection frequency flexibility matters more than precise week-to-week adjustability, long-chain esters like cypionate are practical — a single 10 ml vial covers an extended cycle with minimal injection events. For recomposition, where frequent dose titration may be desirable, shorter esters (propionate, phenylpropionate) allow faster serum correction. Cypionate's depot duration makes it well-suited to stable, consistent mass phases rather than rapid-response dose manipulation.

What is the practical difference between intramuscular and subcutaneous injection for a long-ester depot like Testosterone Cypionate?

Intramuscular injection delivers the oil depot into highly vascularised muscle tissue, resulting in reliable and well-characterised absorption kinetics for long-chain esters like cypionate. Subcutaneous injection places the depot in adipose tissue, where absorption is slightly slower and more variable. Most clinical TRT protocols and bodybuilding administrations use IM delivery; subcutaneous is sometimes preferred for comfort with smaller doses, but Cmax values differ and users should maintain a consistent route to avoid unpredictable serum fluctuations.

How should the Cypilos 10ml vial be stored after the first puncture, and how many doses can it safely provide?

After the rubber stopper is first punctured, Cypilos should be stored upright in a refrigerator (2–8 °C) away from direct light; the multi-dose vial format is designed for repeated access across a cycle. At 250 mg/ml and 10 ml total volume, the vial contains 2,500 mg of Testosterone Cypionate, which equates to 10 weekly 250 mg doses, 5 weekly 500 mg doses, or 20 bi-weekly 125 mg doses depending on the protocol. Use a fresh sterile needle for each withdrawal to maintain stopper integrity.

Can insulin syringes be used to measure and inject Testosterone Cypionate from the Cypilos vial?

Insulin syringes (typically 1 ml / 100-unit format) can measure small volumes of Cypilos accurately — at 250 mg/ml, 0.5 ml equals 125 mg and 1 ml equals 250 mg, which aligns with common dose increments. However, insulin syringe needles (28–31 gauge) are too fine for efficient aspiration of viscous oil; most users draw through a larger-gauge needle (21–23 gauge) then swap to a finer needle for injection. For subcutaneous delivery, a 25–27 gauge, 5/8 inch needle is adequate for both withdrawal and injection. (2) angle_used

Original Product

Driada Medical

Cypilos 250mg/ml 10ml Vial by Driada Medical

Name: Cypilos 250mg/ml 10ml Vial by Driada Medical
Brand: Driada Medical
SKU: INJ-TCYP-DRI-250-006
Price: 36.00 EUR
Availability: InStock

Cypilos by Driada Medical delivers Testosterone Cypionate at 250 mg/ml in a 10 ml multi-dose vial — a long-chain ester depot injectable whose defining clinical characteristic is how its ester structure shapes release kinetics relative to shorter and longer testosterone ester alternatives. Among the injectable ester formats available, the cypionate chain occupies a practical midpoint: slower than propionate, faster-clearing than undecanoate, and broadly comparable to enanthate but with a subtly extended depot window owing to its eight-carbon ester tail. Every Cypilos batch is released only after reversed-phase HPLC potency verification and Bacterial Endotoxin Testing (BET) per Ph. Eur. methodology; both results are documented against certified reference standards before any vial enters distribution.

€36.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Eight-carbon ester structure supports stable weekly dosing without daily injections
250 mg/ml concentration maps cleanly onto standard 1 ml syringe graduation marks
10 ml multi-dose vial format accommodates flexible dose titration across a full cycle
Dual-gate quality control: API tested at raw-material stage and again in finished vial
Bacterial Endotoxin Testing (BET) per Ph. Eur. 2.6.14 confirms parenteral-safe release
Oil-based suspension vehicle reinforces sustained depot release from the injection site
Broader ester context: cypionate outperforms shorter esters in dosing convenience while remaining faster-adjustable than ultra-long undecanoate depots

Phase	Dosage	Note
Introductory / Ester Familiarisation	250 mg/week (1.0 ml)	Single weekly IM injection; establishes baseline serum levels while assessing individual response to the cypionate ester depot
Intermediate Strength / Hypertrophy	400–500 mg/week (1.6–2.0 ml)	Split into two injections per week (e.g. 0.8–1.0 ml each) to smooth the serum gradient consistent with the cypionate release window
Experienced / Stacked Cycle	500–750 mg/week (2.0–3.0 ml)	Cypionate ester allows predictable depot accumulation; combine with an aromatase inhibitor and monitor E2 every 4 weeks via serum assay
Conservative TRT / Clinical Reference	100–200 mg/week (0.4–0.8 ml)	Weekly or fortnightly IM injection; cypionate's depot duration accommodates both schedules — confirm serum testosterone trough levels before adjusting

Key takeaways

Compare ester chain length before selecting your testosterone injection schedule.
Choose cypionate over propionate to cut weekly injection frequency significantly.
Verify both API purity and finished-vial potency via dual-gate HPLC testing.
Match needle gauge to administration route for accurate oil-depot delivery.
Store opened multi-dose vials refrigerated and use a fresh sterile needle each time.

Testosterone Cypionate Defined by Its Ester: What Sets Cypilos Apart

Cypilos is a sterile, oil-suspended injectable formulation in which the cypionate ester determines not just the release duration of free testosterone but the entire practical framework of how, when, and how often the compound must be administered. The ester is the pharmacological lever: it dictates injection frequency, depot longevity, and the gradient of serum fluctuation a user will experience week to week. Understanding Cypilos therefore begins with understanding ester chemistry as a system, not as a footnote.

Testosterone Cypionate carries an eight-carbon ester (cyclopentylpropionate) covalently bonded to the testosterone molecule at the C-17 hydroxyl position. This bond must be cleaved by local esterase enzymes before free testosterone becomes biologically active. Compared to testosterone propionate — a two-carbon ester that releases free hormone within 24–48 hours and demands every-other-day injections — the cypionate ester extends the effective release window to approximately 7–10 days per injection, allowing weekly or twice-weekly dosing schedules without clinically significant trough events. Compared to testosterone undecanoate (eleven-carbon ester, injectable), cypionate clears substantially faster and produces a more responsive serum curve, making mid-cycle dose adjustments more tractable.

Ester Length, Injection Form, and Practical Administration

Driada Medical formulates Cypilos specifically at 250 mg/ml — a concentration that aligns dosing arithmetic with standard insulin-syringe and 1 ml luer-lock syringe formats used in subcutaneous and intramuscular administration. Intramuscular injection into the gluteus medius or vastus lateralis remains the reference route for depot testosterone esters; the oil carrier (typically sesame or grape-seed oil in pharmaceutical-grade preparations) slows diffusion from the injection site and reinforces the sustained-release profile the ester structure already provides.

Syringe selection directly reflects ester-driven dosing logic: a 23–25 gauge, 1–1.5 inch needle is appropriate for IM administration at this viscosity, while subcutaneous delivery with a shorter, finer needle (25–27 gauge, 5/8 inch) is practiced by some TRT patients for comfort, though absorption kinetics differ marginally from the IM route.

Quality Anchors: API Origin and Batch-Release Methodology

Driada Medical sources the Testosterone Cypionate API for Cypilos from suppliers operating under documented supply-chain qualification programmes, with raw material identity and purity confirmed by HPLC assay and infrared spectroscopy against pharmacopoeial reference standards before any batch enters production. This upstream API verification step — independent of the finished-product assay — represents a dual-gate quality architecture: the active pharmaceutical ingredient is tested as a raw material, then re-verified post-formulation in the finished vial. Bacterial Endotoxin Testing (BET) per Ph. Eur. 2.6.14 provides the microbiological release criterion, ensuring that every 10 ml vial of Cypilos meets parenteral safety thresholds before it leaves the facility.

Usage

Verify the vial label confirms Testosterone Cypionate 250 mg/ml and check the batch number against the certificate of analysis before first use.
Allow the Cypilos vial to reach room temperature (approximately 20–25 °C) to reduce oil viscosity and facilitate smooth aspiration — do not apply direct heat.
Swab the rubber stopper with a 70% isopropyl alcohol wipe and allow it to dry fully; insert a 21–23 gauge draw needle to withdraw the required volume, minimising stopper coring.
Swap to the injection needle appropriate for your chosen route — 23–25 gauge, 1–1.5 inch for IM into the gluteus medius or vastus lateralis; 25–27 gauge, 5/8 inch for subcutaneous delivery — and expel any air bubble.
Inject slowly and steadily at the target site; aspirate briefly before depressing the plunger if using IM technique, and rotate injection sites across the cycle to prevent localised depot buildup or fibrosis.
Recap the draw needle (not the injection needle), record the dose and injection date in a cycle log, and store the vial upright under refrigeration (2–8 °C) away from UV light until the next administration.

Warnings

Contraindications: Cypilos is contraindicated in individuals with diagnosed prostate or breast carcinoma, hypersensitivity to testosterone cypionate or any oil-based excipient in the formulation, untreated obstructive sleep apnoea, or active polycythaemia. Women who are pregnant or may become pregnant must not use injectable testosterone esters.

Side Effects: Androgenic effects including accelerated scalp hair thinning, acne, and increased sebaceous gland activity are dose-dependent and ester-independent. Aromatisation of testosterone to oestradiol can produce fluid retention, gynaecomastia, and mood variation; aromatase inhibitor co-administration is typically required at doses above 250 mg/week. Elevated haematocrit is a recognised haematological risk with long-ester depot testosterone; periodic full blood count monitoring is essential.

Monitoring: Serum testosterone (trough, drawn immediately before the next scheduled injection), oestradiol (E2), haematocrit, haemoglobin, and lipid panel (LDL/HDL) should be assessed at 6-week intervals during active cycling. Liver enzymes (ALT/AST) are generally unaffected by injectable esters but serve as a baseline reference. PSA screening is advisable for males over 40 undertaking sustained administration.

PCT: Post-cycle therapy should commence once the cypionate depot has sufficiently cleared — typically 14–21 days after the final injection, reflecting the ester's release kinetics. A SERM-based protocol (e.g. Nolvadex or Clomid) for 4–6 weeks supports hypothalamic-pituitary-gonadal axis recovery. Duration and agent selection should reflect total cycle length and cumulative androgen exposure.

Frequently asked questions

How does the cypionate ester differ from enanthate and propionate in terms of release profile?: Cypionate's eight-carbon ester tail produces an approximate 7–10 day active-release window per injection, sitting between propionate (2-carbon, 24–48 hour release, requiring every-other-day injections) and undecanoate (11-carbon, 2–4 week depot). Compared to enanthate (7-carbon), cypionate releases marginally more slowly due to its slightly longer chain, but the clinical difference is modest — both support weekly or twice-weekly injection schedules with comparable serum stability.
Which testosterone ester is best suited to a strength-focused bulking phase versus a recomposition goal?: For bulking phases where injection frequency flexibility matters more than precise week-to-week adjustability, long-chain esters like cypionate are practical — a single 10 ml vial covers an extended cycle with minimal injection events. For recomposition, where frequent dose titration may be desirable, shorter esters (propionate, phenylpropionate) allow faster serum correction. Cypionate's depot duration makes it well-suited to stable, consistent mass phases rather than rapid-response dose manipulation.
What is the practical difference between intramuscular and subcutaneous injection for a long-ester depot like Testosterone Cypionate?: Intramuscular injection delivers the oil depot into highly vascularised muscle tissue, resulting in reliable and well-characterised absorption kinetics for long-chain esters like cypionate. Subcutaneous injection places the depot in adipose tissue, where absorption is slightly slower and more variable. Most clinical TRT protocols and bodybuilding administrations use IM delivery; subcutaneous is sometimes preferred for comfort with smaller doses, but Cmax values differ and users should maintain a consistent route to avoid unpredictable serum fluctuations.
How should the Cypilos 10ml vial be stored after the first puncture, and how many doses can it safely provide?: After the rubber stopper is first punctured, Cypilos should be stored upright in a refrigerator (2–8 °C) away from direct light; the multi-dose vial format is designed for repeated access across a cycle. At 250 mg/ml and 10 ml total volume, the vial contains 2,500 mg of Testosterone Cypionate, which equates to 10 weekly 250 mg doses, 5 weekly 500 mg doses, or 20 bi-weekly 125 mg doses depending on the protocol. Use a fresh sterile needle for each withdrawal to maintain stopper integrity.
Can insulin syringes be used to measure and inject Testosterone Cypionate from the Cypilos vial?: Insulin syringes (typically 1 ml / 100-unit format) can measure small volumes of Cypilos accurately — at 250 mg/ml, 0.5 ml equals 125 mg and 1 ml equals 250 mg, which aligns with common dose increments. However, insulin syringe needles (28–31 gauge) are too fine for efficient aspiration of viscous oil; most users draw through a larger-gauge needle (21–23 gauge) then swap to a finer needle for injection. For subcutaneous delivery, a 25–27 gauge, 5/8 inch needle is adequate for both withdrawal and injection. (2) angle_used

Manufacturer

Driada Medical's approach to API sourcing for Cypilos centres on a qualification framework applied upstream — before any raw Testosterone Cypionate enters the manufacturing suite. Supplier APIs are subjected to identity confirmation via infrared spectroscopy and purity quantification by reversed-phase HPLC, benchmarked against pharmacopoeial reference standards; only materials meeting defined specification limits proceed to formulation. This raw-material gate is separate from and in addition to the finished-product release assay, creating an independent verification layer at each stage of the supply chain. The origin of the API is governed by Driada Medical's documented vendor qualification programme, which requires suppliers to provide certificates of analysis traceable to individual synthesis batches — a chain-of-custody requirement that connects each Cypilos vial back to a characterised and approved starting material. Finished-vial release is further conditional on Bacterial Endotoxin Testing (BET) per Ph. Eur. 2.6.14, providing the microbiological safeguard required for all parenteral products before distribution.

Product details

Brand	Driada Medical
Active ingredient	testosterone cypionate
Also known as	Testosterone Cypionate, Test C, Depo-Testosteronee, Cypilos, Driada Medical Testosterone Cypionate
Strength	250 mg
Form	Vial
Pack size	1 piece
Item number	INJ-TCYP-DRI-250-006

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Cipandrol 200mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Cipandrol 200mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Cipandrol is a pharmaceutical-grade injectable testosterone preparation built around Testosterone Cypionate at 200 mg/ml — a compound whose origins trace back to American clinical research of the 1950s, when chemists at Upjohn first attached the cypionate ester to extend testosterone's therapeutic window. Presented in individual glass ampoules (10 × 1 ml), each unit delivers a precise, single-use dose free from the cross-contamination risk inherent in repeatedly punctured multi-dose vials. Sterility and potency are verified through independent HPLC quantification and LAL endotoxin screening conducted at Balkan Pharmaceuticals' GMP-certified Chișinău facility.

€38.00

High Concentration

Cypo-Testosterone 200mg/ml 10ml Vial by Beligas Pharmaceuticals

Cypo-Testosterone by Beligas Pharmaceuticals is a single-ingredient injectable androgen — Testosterone Cypionate at 200 mg per millilitre in a 10 ml multi-dose vial — engineered specifically to slot into structured, periodised cycle frameworks. At this concentration, each 1 ml draw delivers a precise 200 mg dose, giving cycle planners clean arithmetic when calculating weekly volume across bulking, maintenance, or recomposition phases. Quality assurance is enforced at every stage: HPLC-verified potency, LAL endotoxin testing, and GMP-certified filling conditions underpin every vial released under the Beligas label.

€38.00

Testacyp-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Testacyp-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Testacyp-250 is an oil-based injectable testosterone ester in which Testosterone Cypionate at 250 mg/ml is engineered around its extended pharmacokinetic profile — delivering a clinically measurable half-life of approximately 8 days that sustains androgen receptor saturation between injections. Each 1 ml single-dose ampoule provides precise, pre-measured delivery in a hermetically sealed format that eliminates multi-use contamination risk. Quality assurance at BM Pharmaceuticals is built into every production stage: HPLC potency verification, LAL endotoxin screening, and GMP-certified fill-finish operations underpin every released batch.

€38.00

Brand Quality

CypioTrex 350mg/ml 10ml Vial by Concentrex Labs

CypioTrex is a high-concentration testosterone cypionate injectable — 350 mg/ml in a 10 ml multi-dose vial — engineered specifically for athletes running structured cruise-and-blast protocols that require distinct, clearly separated androgenic phases. At 350 mg/ml, each millilitre delivers 75% more active compound than standard 200 mg/ml preparations, reducing injection volume while maintaining full dosing flexibility across both the high-output blast window and the lower-dose cruise interval. Every batch is released only after passing in-house HPLC potency verification and LAL endotoxin screening, with GMP-aligned documentation supporting each production stage.

€38.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00